---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Heterogeneity of treatment effect"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Heterogeneity of treatment effect. Topics: Typical CIDP and CIDP variants, Antibody-mediated nodopathies: response to standard therapy, Antibody subclass and expected relevance of complement inhibition, Response by prior immunoglobulin exposure, and 4 further topics. 8 evidence topics quoted from 9 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/heterogeneity-of-treatment-effect"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Heterogeneity of treatment effect

<a id="heading-2.2.2.3"></a>

## 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

### Typical CIDP and CIDP variants

> “Patients were diagnosed with typical CIDP (69.2%) and variant CIDP (30.8%).”

Source: [Querol et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12361836/)

> “A diverse and complex interplay of different immunopathological mechanisms, involving cellular, humoral and complement pathways, culminates in a highly variable pattern of peripheral nerve damage in different clinical variants of CIDP.”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

> “Participants must have typical, motor or multifocal CIDP.”

Source: [Allen et al. (2026d)](https://investor.dianthustx.com/static-files/61f3f3f9-f022-43e3-86d2-8534e2df4ac9)

<a id="topic-2.2.2.3-2"></a>

### Antibody-mediated nodopathies: response to standard therapy

> “A breakthrough in CIDP antibody autoimmunity has been the remarkable observation that a subset of patients who do not respond to IVIg or plasmapheresis have IgG4 antibodies to nodal/paranodal antigens directed against neurofascin-155 (Nfasc155), neurofascin-140/186 (Nfasc140/186), contactin-1 (CNTN1), and contactin-associated protein 1 (Caspr1)”
> “Because the IgG4 antibodies do not trigger inflammatory processes or complement-mediated immune responses, the conventional anti-inflammatory therapies, especially with IVIg, immunosuppressants, and plasmapheresis, are ineffective or not sufficiently effective in inducing long-term remissions.”
> “Indeed, data from large series of patients with MuSK myasthenia, CIDP with nodal/paranodal antibodies, and anti-LGI1 and CASPR2-associated syndromes indicate that B cell depletion therapy with rituximab exerts long-lasting clinical remissions by targeting memory B cells and IgG4-producing CD20-positive short-lived plasma cells.”

Source: [Dalakas (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294117/)

<a id="topic-2.2.2.3-3"></a>

### Antibody subclass and expected relevance of complement inhibition

> “It is noteworthy that almost all the antibodies to these paranodal antigens were IgG4, an IgG subclass that is non-complement fixing”
> “Nonetheless, some variants of these neuropathies harbor IgG1-3 subclass of antibodies with ability to fix complement and could potentially be candidates to complement inhibition”
> “However, complement involvement in certain subgroups of CIDP patients, including those with non-complement fixing antibodies, is not yet certain”

Source: [Querol et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9294101/)

<a id="topic-2.2.2.3-4"></a>

### Response by prior immunoglobulin exposure

> “IVIG-pretreated patients demonstrated a higher responder rate than IVIG-naïve patients (76.9% vs. 46.7%).”

Source: [Léger et al. (2013)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3910165/)

<a id="topic-2.2.2.3-5"></a>

### Response by disease course to plasma exchange

> “Fifteen patients completed the trial and of those, 12 patients (80%) improved substantially with PE; i.e. five out of seven patients with chronic progressive course and seven out of eight patients with relapsing CIDP improved.”
> “The PE non-responders improved with prednisone.”

Source: [Hahn et al. (1996)](https://pubmed.ncbi.nlm.nih.gov/8813270/)

<a id="topic-2.2.2.3-6"></a>

### Non-response and alternative diagnoses

> “Alternative diagnosis was made in 7 out of 12 (58%) who did not respond to any therapy and in none of the treatment-responsive patients.”
> “In treatment-nonresponsive patients, the diagnosis CIDP should be reconsidered.”

Source: [Eftimov et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22442436/)

<a id="topic-2.2.2.3-7"></a>

### Activated C1s inhibition by standard-of-care group: riliprubart phase 2

> “This open-label, Phase-2 trial evaluates riliprubart across three groups: Standard-of-care (SoC)-Treated, SoC-Refractory, and SoC-Naïve.”
> “At Week-24, Part-A interim-analysis showed 87% (N=42/48) SoC-Treated participants improved/remained stable (improved: 52%; N=25/48) after directly switching from SoC to riliprubart. 50% (N=9/18) SoC-Refractory, and 75% (N=9/12) SoC-Naïve participants responded to riliprubart”

Source: [Querol et al. (2026d)](https://index.mirasmart.com/AAN2026/PDFfiles/AAN2026-000633.html)

<a id="topic-2.2.2.3-8"></a>

### Neonatal Fc receptor blockade by prior treatment status

> “Clinically meaningful improvements in disability and strength were observed across assessments, regardless of stage B treatment or prior treatment status, with greater improvements seen over time.”

Source: [Allen et al. (2026c)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13375598/)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
